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Abstract
Background: S100B is considered an astrocytic in-situ marker and protein levels in cerebrospinal
fluid (CSF) or serum are often used as biomarker for astrocytic damage or dysfunction. However,
studies on S100B in the human brain are rare. Thus, the distribution of S100B was studied by
immunohistochemistry in adult human brains to evaluate its cell-type specificity.
Results: Contrary to glial fibrillary acidic protein (GFAP), which selectively labels astrocytes and
shows only faint ependymal immunopositivity, a less uniform staining pattern was seen in the case
of S100B. Cells with astrocytic morphology were primarily stained by S100B in the human cortex,
while only 20% (14–30%) or 14% (7–35%) of all immunopositive cells showed oligodendrocytic
morphology in the dorsolateral prefrontal and temporal cortices, respectively. In the white matter,
however, most immunostained cells resembled oligodendrocytes [frontal: 75% (57–85%);
temporal: 73% (59–87%); parietal: 79% (62–89%); corpus callosum: 93% (86–97%)]. S100B was also
found in ependymal cells, the choroid plexus epithelium, vascular endothelial cells, lymphocytes,
and several neurones. Anti-myelin basic protein (MBP) immunolabelling showed an association of
S100B with myelinated fibres, whereas GFAP double staining revealed a distinct subpopulation of
cells with astrocytic morphology, which solely expressed S100B but not GFAP. Some of these cells
showed co-localization of S100B and A2B5 and may be characterized as O2A glial progenitor cells.
However, S100B was not detected in microglial cells, as revealed by double-immunolabelling with
HLA-DR.
Conclusion: S100B is localized in many neural cell-types and is less astrocyte-specific than GFAP.
These are important results in order to avoid misinterpretation in the identification of normal and
pathological cell types in situ and in clinical studies since S100B is continuously used as an astrocytic
marker in animal models and various human diseases.
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1. Background
S100B protein is a Ca2+, Cu2+ and Zn2+ binding member
of the S100-calmodulin-troponin superfamily and is pri-
marily found in high abundance within the nervous sys-
tem [1].
21 kDa homodimers are the predominant form in which
the protein exists within cells. A number of intracellular
growth-associated target proteins have been revealed,
such as growth-associated protein 43 (GAP-43), the regu-
latory domain of protein kinase C (PKC), the anti-apop-
totic factor Bcl-2 or the tumour suppressor protein P53
[2]. S100B has also been found to regulate protein ubiq-
uitination via interaction with Sgt1 [3] and regulate the
assembly of cytoskeleton components such as microtu-
bules, glial fibrillary acidic protein (GFAP) or vimentin
[4].
However, S100B is not only implicated in the regulation
of intracellular processes, but, it is also a secretory protein
and exhibits cytokine-like activities, which mediate the
interactions among glial cells and between glial cells and
neurones. These effects are induced, in part, by interaction
of S100B with the receptor for advanced glycation end
products (RAGE), a multiligand receptor that has been
shown to transduce inflammatory stimuli and effects of
several neurotrophic and neurotoxic factors [2]. Secretion
of S100B from astrocytes is stimulated under metabolic
stress (oxygen, serum and glucose deprivation) and is sup-
pressed by glutamate [5,6]. S100B acts in a dose-depend-
ent manner: Nanomolar levels stimulate neurite growth
and promote neurone survival. However, micromolar lev-
els result in opposite effects and can even induce neuronal
apoptosis, leading to the induction of pro-inflammatory
cytokines such as interleukin1β (IL-1β) or tumour necro-
sis factor α (TNF-α), and inflammatory stress-related
enzymes such as inducible nitric oxide synthase (iNOS)
[7,8].
High levels of S100B in cerebrospinal fluid (CSF) and
peripheral blood have been observed in clinical research
on Alzheimer's disease, stroke, traumatic brain injury,
meningoencephalitis, mood disorders and schizophrenia
[9-13]. Elevated levels of S100B have been increasingly
considered a biomarker for astrocytic damage or dysfunc-
tion in this context. This may have arisen from several
postmortem studies on Alzheimer's disease and Down's
syndrome describing predominant S100B immunostain-
ing in reactive astrocytes surrounding neuritic plaques
[14-16]. Other studies on the cell-type specificity of S100B
in human brain are rare [17,18]. The cell-type specific
localization of S100B in white matter has been minimally
studied in human brain. However, higher contents of
S100 have been found in white matter homogenates rela-
tive to cortex homogenates by the discoverer of the pro-
tein family [19].
In addition, it is sometimes overlooked that S100B con-
taining cell types have also been identified outside the
central nervous system and there are physiological stimuli
for a release of S100B into the serum or CSF, which are not
related to central nervous system diseases. Examples are
physical exercise [20], stress [21,22], fasting [23], critically
ill patients [24], cardiac arrest [25] and extracranial inju-
ries [26,27] without brain injury.
The aim of the present work was to analyze the immuno-
histochemical distribution of S100B in adult human
brain. We investigated telencephalic and diencephalic
regions, including white matter of 14 healthy adults, to
evaluate the cell-type specificity of S100B.
2. Results
Western blot analysis
Using the S100B antibody obtained from DAKO, we
observed a single strong band with a molecular mass of
about 10 kDa, representing the authentic molecule, in
human adult brain (Figure 1). This is in accordance with
the immunoblotting analysis performed by the manufac-
turer of the antibody (DAKO, Glostrup, Denmark, see
data sheet) using recombinant S100A1, S100A2, S100A4
and S100A6, where no cross-reaction with other S100
proteins was observed.
Preabsorption
No specific immunostaining was observed after preab-
sorption of the S100B antibody with the recombinant
human-S100B protein.
Immunohistochemistry – Single staining
The differential S100B- and GFAP-immunostaining pat-
tern is summarized in Table 1 and 2. GFAP immunohisto-
chemistry selectively labelled astrocytes and their
processes (Figure 2a), showed only faint ependymal
immunopositivity and was negative in the choroid plexus
epithelium (Figure 2e, g). In contrary, a less uniform
staining pattern was seen in the case of S100B. Cells with
astrocytic morphology in the human cortex primarily
stained positive for S100B, while only 20% (14–30%) or
14% (7–35%) of all immunopositive cells showed oli-
godendrocytic morphology in the dorsolateral prefrontal
and temporal cortex, respectively. In the white matter,
however, most immunostained cells resembled oli-
godendrocytes [frontal: 75% (57–85%); temporal: 73%
(59–87%); parietal: 79% (62–89%); corpus callosum:
93% (86–97%); Figure 2b, d]. Both GFAP- and S100B-
immunostaining were seen in the subependymal layer
and the perivascular (glia limitans) compartment and the
perivascular membrane formed by astrocytic endfeet (Fig-BMC Neuroscience 2007, 8:2 http://www.biomedcentral.com/1471-2202/8/2
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ure 2c, e, f). Of note, we observed strong S100B immuno-
positivity of the ependymal and choroids plexus epithelia
(Figure 2f, h). In addition, S100B was also found in a few
neurones and a subpopulation of lymphocytes (Figure 2i,
k). By contrast, GFAP expression was detected neither in
neurones nor in lymphocytes by the monoclonal anti-
body. The intracellular localization also varied: S100B was
found in the nucleus and cytoplasm whereas GFAP was
confined to the cytoplasm.
Double immunolabelling and immunofluorescence staining
Double immunolabelling revealed a distinct subpopula-
tion of cells with astrocytic morphology, which were
either positive for S100B or GFAP, or expressed both anti-
gens (Figure 3a, b). Some of these were A2B5-immunop-
ositive O2A glial progenitor cells (Figure 3f). S100B-
positive fibres were also observed, which correspond to
myelinated fibers as shown by double immunolabelling
for S100B and MBP (Figure 3c, d). Oligodendrocytic
S100B expression was confirmed by co-localization with
MOG (Figure 3e). However, no microglial S100B immu-
nolabelling was observed by HLA-DR double immunos-
taining (Figure 3g).
3. Discussion and Conclusion
The cell-type specific localization of S100B in the brain
has already been investigated in various species, including
mouse, rat, cat, and lizard [28-33]. These studies found
S100B in all glial cells, including astrocytes, ependymal
cells, oligodendrocytes, microglial and Schwann cells.
Studies on the cell-type specific expression of S100B in
human brain are rare, but astrocytic and oligodendrocytic
expression have been observed [23,47]. Immunohisto-
chemical postmortem studies on S100B in human tempo-
ral cortex in Alzheimer's disease and Down's syndrome
may have led to the assumption that S100B is an astro-
cyte-specific marker (see introduction) [13,28,44]. This is
in accordance with our findings on grey matter, indicating
a predominantly astrocytic S100B expression pattern in
the dorsolateral prefrontal and temporal cortex of individ-
uals without neurological or psychiatric disorders. How-
ever the majority of S100B immunopositive cells in the
S100B immunoblot (DAKO, Glostrup, Denmark, dilution 1:500) indicating a single band of S100B protein in human brain  homogenates Figure 1
S100B immunoblot (DAKO, Glostrup, Denmark, dilution 1:500) indicating a single band of S100B protein in human brain 
homogenates.BMC Neuroscience 2007, 8:2 http://www.biomedcentral.com/1471-2202/8/2
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GFAP- and S100B-single immunostaining Figure 2
GFAP- and S100B-single immunostaining. (a) GFAP immunohistochemistry of the border between temporal cortex and 
adjacent white matter selectively labels star-shaped astrocytes and their processes. Blood vessels appear to be GFAP-positive 
because of their close association with pericapillary endfeet. (b) In contrast, various glial cell types are expressing S100B in this 
brain region, such as star-shaped cells with astrocytic morphology (black arrow) and spheroid cells with oligodendrocytic mor-
phology (white arrow). (c) S100B stained astrocytic end feet (arrow: glial perivascular membrane) surround vascular endothe-
lial cells. (d) "Pearl necklet" alignment of S100B positive (black arrow) and negative (white arrow) cells with oligodendrocytic 
morphology are associated with fibre tracts of the corpus callosum. Cytoplasmic and nuclear distribution of S100B is shown in 
the detail-picture. (e) The ependymal layer [E] around the lateral ventricle shows only weak GFAP staining, whereas the sub-
ependymal layer [S] shows intense staining of astrocytes and astrocytic processes. (f) Strongly S100B immunopositive ependy-
mal [E] and subependymal [S] layers around the lateral ventricle. (g) Ependymal cells of the choroid plexus do not express 
GFAP but are heavily stained for S100B (h); some S100B-positive cells display apical secrete granules; arrows indicate cells 
with cytoplasmic versus cytoplasmic and nuclear S100B expression. (i) S100B immunopositive CA1 hippocampal neurone. 
Neurones are rarely S100B positive. (k) S100B immunopositive lymphocytes and vascular smooth muscle cells. The detail pic-
ture shows a S100B stained lymphocyte from a blood smear. Bars: a, b = 100 μm; d, e, f, g, h, I, k = 50 μm; c, d (detail), k 
(detail) = 20 μm.BMC Neuroscience 2007, 8:2 http://www.biomedcentral.com/1471-2202/8/2
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white matter resembled oligodendrocytes, which is in
accordance with an early publication by Moore et al. (the
discoverer of S100) who observed a higher content of
S100 in white matter homogenates relative to cortical
homogenates [19]. It has been demonstrated in rodents
that S100B is primarily confined to immature oli-
godendrocytes, which may be activated in the context of a
regenerative myelination processes [28,31,34,35].
Deloulme et al. [28] detected S100B protein in up to 40%
of MBP-positive oligodendrocytes in the corpus callosum
of mice and Rickmann et al. [34] found an association of
S100B with paranodal loops and outer mesaxons of mye-
lin sheaths in rats by electron microscopic immunohisto-
chemistry.
Microglial staining has only been detected in the rat by
Adami et al. so far, but has not been observed in our
present study on human brain [30]. Our study is the first
reporting of a small subpopulation of S100B containing
neurones in human brain tissue. This is in accordance
with findings in the mouse [29,36] and rat [33,37], but is
in contrary to Li et al., who was unable to detect S100B
immunopositive neurones in adult human brain [18].
Using a different antibody (mouse monoclonal anti-
S100B from IBL, Minnesota) and the absence of antigen
demasking techniques in the study by Li et al. might
explain these different observations, as the importance of
antigen retrieval methods to detect S100B immunoposi-
tive neurones has already been addressed by Yang et al. in
mice [37].
Interestingly, the ependyma and the choroid plexus epi-
thelia were strongly S100B immunopositive in our study
as previously noted in the rat [38]. The surface ependyma
is known to express epithelial markers and faint GFAP-
staining. It is considered to be developmentally related to
astrocytes, while the choroid plexus epithelium is a spe-
cialized ependyma, which differs from the surface epend-
yma: vimentin, cytokeratin and S100B continue to be
expressed, but GFAP is not expressed [39]. Thus, the
observed distribution pattern of S100B in the present
study on human brain completely matches that reported
in mouse and rat, indicating that cellular function might
be very similar among mammalians.
Our study reveals a subpopulation of cells with astrocytic
morphology, which were only immunopositive for S100B
but not for GFAP. One explanation might be that some
cells with astrocytic morphology were S100B- and A2B5-
immunopositive O2A glial progenitor cells, which do not
express GFAP [40].
In conclusion, S100B is a less astrocyte-specific marker
than GFAP. Therefore, it should not be generally assumed
that astrocytic damage or dysfunction is the main source
for increased S100B concentrations in the case of studies
with plasma, serum or cerebrospinal fluid. S100B may
also be released during non-astrocyte cell death as it is
also localized in O2A glial progenitor cells, oligodendro-
cytes, ependymal and plexus epithelial cells and neu-
rones. In addition, S100B protein has also been noted
Table 1: Cell-type specific S100B- and GFAP-immunostaining pattern. Annotation: ∅ immunonegative, + faint immunostaining, ++ 
strong immunostaining
Cell type S100B GFAP
Astrocytes ++, cytoplasm/nuclei ++, cytoplasm and processes
Oligodendrocytes ++, cytoplasm/nuclei ∅
Neurones very few +, cytoplasm/nuclei ∅
Ependyma ++, cytoplasm/nuclei +, cytoplasm
Choroid plexus epithelium ++, cytoplasm/nuclei ∅
Lymphocytes ++, cytoplasm/nuclei ∅
Table 2: Quantification of S100B immunopositive cells with astrocytic versus oligodendrocytic morphology. Annotation: Values are 
given as mean ± S.D.; DLPF dorsolateral prefrontal
Brain region Oligodendrocytic 
S100B+ [cells/mm3]
Astrocytic S100B+
 [cells/mm3]
Oligodendrocytic S100B+ cells 
[mean % of all S100B+ glial cells (min % – max %)]
DLPF cortex 1.247 ± 672 5.066 ± 2.674 20 (14 – 30)
DLPF white matter 14.423 ± 7.061 4.462 ± 2.376 75 (57 – 85)
Temporal cortex 1.207 ± 860 7.457 ± 3.964 14 (7 – 35)
Temporal white matter 11.229 ± 5.085 3.919 ± 2.310 73 (59 – 87)
Parietal white matter 9.279 ± 4.074 2.346 ± 1.357 79 (62 – 89)
Corpus callosum 10.038 ± 4.533 674 ± 338 93 (86 – 97)BMC Neuroscience 2007, 8:2 http://www.biomedcentral.com/1471-2202/8/2
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Double immunostaining and immunofluorescence staining Figure 3
Double immunostaining and immunofluorescence staining. (a) S100B (red)/GFAP (black) double immunolabelling 
with haematoxylin-counterstaining (blue) revealed distinct populations of cells with astrocytic morphology in the temporal cor-
tex. White arrows indicate S100B single positive cells with astrocytic morphology; black arrows indicate GFAP immunopositive 
cells with astrocytic morphology. (b) Temporal brain region (overview): The majority of GFAP immunopositive (black) astro-
cytes were found in the glial limitans and perivascular membrane or in the adjacent white matter. Less GFAP immunopositive 
cells were observed in the cortex. (c) Temporal cortex and adjacent white matter (higher magnification): S100B positive (red) 
radial fibres and oligodendrocytes (white arrows) are shown in comparison to GFAP positive (black) astrocytes; haematoxylin-
counterstaining (blue). (d) Co-localization (yellow) of S100B (red) and MBP-positive (green) myelinated fibres, extending from 
the temporal cortex to the adjacent white matter. (e) Co-localization (yellow) of S100B (red) and MOG-positive (green) oli-
godendrocytes. (f) Co-localization (yellow) of S100B (red) and A2B5-immunopositive (green) O2A glial progenitor cells in the 
temporal cortex. (g) No co-localization (yellow) was observed for S100B (red) and microglial HLA-DR (green). Bars: a = 100 
μm; b = 500 μm; c = 30 μm.BMC Neuroscience 2007, 8:2 http://www.biomedcentral.com/1471-2202/8/2
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outside the central nervous system. Immunocytochemical
studies detected S100B in 5–25% of CD8+ peripheral
blood T cells [41], in adipose tissue, melanocytes, injured
myocardium, satellite cells of dorsal root ganglia and
Schwann-cells of the peripheral nervous system [2]. There
is little information about the functional implications,
but all these cell types are potential sources for S100B in
serum.
In contrast, only minor sources of GFAP have been
detected outside the central nervous system. Traces of
GFAP have been found in the peripheral nervous system,
macrophages, lymphocytes, lens epithelial cells, and few
human breast myoepithelial cells [42-45]. Moreover, the
peripheral GFAP is a shorter protein version and may be
antigenically and structurally different, as monoclonal anti-
brain GFAP antibodies have failed to recognize peripheral
GFAP [46,47].
In summary, serum and CSF S100B, different from GFAP,
has many putative cellular sources. This is important to
avoid misinterpretation of normal and pathological cell
type identifications in situ and in clinical studies since
S100B is continuously used as an astrocytic marker in ani-
mal models and various human diseases.
4. Methods
Human brain tissue for Western blot analysis and 
immunofluorescence staining
The brain of a 32 year old woman (who died from acute
myocarditis associated with lupus) was removed from the
cranium within 20 hrs after death, dissected into small
pieces, snap-frozen in liquid nitrogen and stored.
Human brain tissue for immunohistochemistry
Postmortem brain tissue of 14 individuals without neuro-
logical or psychiatric disorders was used for the present
study (mean age = 58.4 years; 7 males, 7 females). All
brains were obtained from the Magdeburg Brain Collec-
tion. The collection of the human brain material was done
in accordance with German laws and the rules outlined by
the local ethics committee. Brains were removed within
48 hrs after death. The tissue preparation was performed
as previously described [48]. Briefly, brains were fixed in
toto in 8% phosphate-buffered formaldehyde (pH 7.0)
for 3 months. After embedding the brains in paraplast,
serial coronal 20 μm thick whole brain sections were cut
on a microtome and mounted. For immunohistochemi-
cal staining, sections about 1 cm rostral to the genu of the
corpus callosum and sections containing the hippocam-
pus, as well as thalamus and lateral ventricles at the level
of the mamillary bodies were selected.
Blood smears from two healthy subjects were stained for
S100B for closer identification of S100B immunopositive
white blood cells, which were found in the vessels of brain
sections. The blood smears were fixed in methanol for 1 h.
Western blot analysis
Frozen tissue samples from the temporal cortex and cere-
bellum was homogenized in lysis buffer [10 mM Tris (pH
7.4), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 1% Triton
X-100, 0.1% SDS, 0.5% deoxycholat, 2.5 mM sodium
pyrophosphate, 1 mM orthovanadate, 1 mM phenylmeth-
ylsulfonyl fluoride, 1 μg/ml leupeptin, and 10 μg/ml
aprotinin, 1 mM DTT], and incubated on ice for 30 min-
utes. After centrifugation at 13,000 rpm for 15 minutes,
the supernatant was collected to measure the total protein
content. Protein concentration was measured by Bradford
assay, with BSA as standard. Twenty micrograms of pro-
tein were loaded on 10% SDS-polyacrylamide gels for
electrophoresis. After separation, proteins were trans-
ferred to a nitrocellulose membrane (Hybond C, Amer-
sham Pharmacia Biotech, Freiburg, Germany) at 150 mA
for 2 hours. Western blot analysis was done after blocking
the membrane with 5% skim milk in TBST buffer for 1
hour. The membrane was incubated with the specific
S100B antibody at 4°C overnight (DAKO, Glostrup, Den-
mark, dilution 1:500). The membrane was washed four
times in TBST buffer. Secondary detection was performed
using horseradish peroxidase-conjugated anti-rabbit
immunoglobulin G (1:2,000; Amersham Pharmacia Bio-
tech). After four washings with TBST, horseradish peroxi-
dase activity was visualized by applying enhanced
chemiluminescent substrate (Amersham Pharmacia Bio-
tech) followed by exposure of the membrane to X-ray
film.
Immunohistochemistry
Neighbouring sections were used for S100B or GFAP sin-
gle-staining. Formalin-fixed tissue sections were deparaffi-
nized and antigen demasking was performed by boiling
the sections for 4 min in 10 mM citrate buffer (pH 6.0).
Preincubation with 1.5% H2O2  for 10 min to block
endogenous peroxidase activity was followed by blocking
of nonspecific binding sites with 10% normal goat serum
for 60 min and repeated washings with PBS. The primary
antibody was diluted in PBS and applied for 48 h at 4°C
(both antibodies were from DAKO, Glostrup, Denmark:
polyclonal rabbit anti-recombinant human S100B,
according to the manufacturer non cross-reactive with
S100A1, S100A2, S100A4, and S100A6, dilution 1:50;
monoclonal mouse anti-human brain glial fibrillary
acidic protein (GFAP), dilution 1:100). Thereafter, sec-
tions were processed with the LSAB (labelled streptavidin
biotin) method (DAKO, Glostrup, Denmark) and the
reaction product was visualized with 3,3-diaminobenzi-
dine. The colour reaction of the S100B staining was
enhanced by adding 2 ml of a 0.5% (v/v) nickel ammo-
nium sulphate solution to the diaminobenzidine [49].BMC Neuroscience 2007, 8:2 http://www.biomedcentral.com/1471-2202/8/2
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Preabsorption: Specificity of the S100B immunoreaction
was controlled by preabsorption of 2 ml antibody work-
ing dilution with 0.8 mg recombinant human-S100B
(Biotrend, Cologne, Germany) for 24 h. No specific stain-
ing was observed after preabsorption with the protein.
Double staining: Anti S100B primary antibody was applied
for 48 h at 4°C. Thereafter, sections were incubated with
EnVision Labelled Polymer (alkaline phosphatase-
labelled anti-mouse and anti-rabbit antibodies, DAKO,
Glostrup, Denmark) and the reaction product was visual-
ized with Liquid permanent red (DAKO, Glostrup, Den-
mark). Subsequent GFAP immunostaining was
performed according to the single-staining protocol after
antibody elution with 0.1 M glycine-HCl for 10 min (pH
2.0). Counterstaining was performed with 50% (v/v)
Harris Haematoxylin Solution (Sigma, St. Louis, USA) for
30 s.
Immunofluorescence staining
A tissue sample from the temporal cortex and adjacent
white matter was fixed in 4% buffered paraformaldehyde
(pH 7.4) at 4°C overnight, cryoprotected in a solution of
30% sucrose (Merck, Darmstadt, Germany) in 0.4% buff-
ered paraformaldehyde (pH 7.4) for 2 days, and rapidly
frozen at -20°C using 2-methylbutane (Roth, Karlsruhe,
Germany). Serial sagittal 20 μm thick sections were cut on
a cryostat (Jung Frigocut 2800 E, Leica, Bensheim, Ger-
many).
Free-floating sections were washed and incubated with
the corresponding antibodies: polyclonal rabbit anti-
recombinant human S100B (DAKO, Glostrup, Denmark,
dilution 1:50), monoclonal mouse anti-myelin basic pro-
tein (anti-MBP, Chemicon, Hampshire, United Kingdom,
dilution 1:100), monoclonal mouse anti-myelin oli-
godendrocyte glycoprotein (anti-MOG, Chemicon,
Hampshire, United Kingdom, dilution 1:500), mono-
clonal mouse anti-A2B5 (Chemicon, Hampshire, United
Kingdom, dilution 1:100), or monoclonal mouse anti-
human HLA-DR-alpha-chain (Clone TAL.1B5, DAKO,
Glostrup, Denmark, dilution 1:1000) in PBS with 0.3%
Triton X-100 and 1% normal goat serum overnight at
4°C. Following this, slices were washed in PBS (3 × 5 min)
and incubated overnight with a combination of secondary
antibodies (Molecular Probes, Göttingen, Germany, dilu-
tion 1:500): goat anti-rabbit-IgG Alexa Fluor 546 or goat
anti-mouse-IgG Alexa Fluor 488. Sections were examined
using a fluorescence microscope (Axiophot, Zeiss, Ger-
many) equipped with fluorescein, rhodamine and DAPI
optics. Control reactions (substitution of the primary
antisera with PBS) yielded negative results, i.e. no specific
immunostaining was seen in these sections.
Cytological classification
The  cytological classification of immunopositive cells as
neurones, astrocytes, oligodendrocytes or microglia was
performed according to established cytomorphological
criteria [50]: Neuronal nuclei are large, round with a sin-
gle prominent nucleolus ("fried-egg" nuclei) and are sur-
rounded by substantial cytoplasm. Astrocytes have less
cytoplasm surrounding large, more or less rounded nuclei
and exhibit many star-shaped processes. Fibrous astro-
cytes are found predominantly in the white matter; they
possess numerous elongated processes. Protoplasmic
astrocytes are present among collections of neuronal cell
bodies (grey matter). Their processes are less numerous
and considerably more swollen in appearance than those
of fibrous astrocytes. Oligodendrocytes are associated
with fibre tracts in typical "pearl necklet" alignment. They
are small spheroid glial cells with round, lymphocyte-like
nuclei, a small cytoplasmic rim and few processes (less
than astrocytes).
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